Learn More
Immunogenic peptide-based vaccines can raise significant cellular immune responses. Although cytotoxic T lymphocytes (CTL) peptide epitopes are generally poor immunogens, heat shock protein 70 from Mycobacterium tuberculosis (TBhsp70) can overcome this problem since it is a potent adjuvant that links innate and adaptive immune responses. Our goal is to use(More)
BACKGROUND The Hepatitis C virus (HCV) core protein has been implicated as a potential oncogene or a cofactor in HCV-related hepatocellular carcinoma (HCC), but the underlying mechanisms are unknown. Overactivation of the Wnt/β-catenin signaling is a major factor in oncogenesis of HCC. However, the pathogenesis of HCV core-associated Wnt/β-catenin(More)
BACKGROUND To date, few studies have been conducted to determine whether T cell receptor (TCR) gammadelta T cells are involved in hepatitis B virus (HBV) infection. This study was performed to assess the quantity and immune function of TCRgammadelta T cells in the blood of patients with chronic HBV infection and to analyze the relationship between(More)
BACKGROUND The hepatitis B virus (HBV) DNA vaccine can generate both HBsAg-specific humoral and cellular immune responses. The immune response can be improved by inclusion of an adjuvant, such as the cytokine GM-CSF which is known to be a very good adjuvant. METHODS To investigate the ability of GM-CSF to enhance HBV-DNA vaccines, we constructed the(More)
BACKGROUND γδ T cells play an important role in infectious, autoimmune, or neoplastic diseases. Here, a study was conducted to investigate the dynamic changes in phenotype and function of peripheral γδ T cells in patients with chronic hepatitis B (CHB) during pegylated-interferon (pegIFN)-α treatment, and to explore their roles in IFN-α therapy. METHODS(More)
BACKGROUND Hepatitis B virus (HBV) infection has a tendency to be chronic. The quasi species of HBV in the pre-S/S gene and mutations in enhancer II (EnhII)/core promoter (CP)/pre-C of HBV were studied in asymptomatic carrier (AsC) mothers and their children with different virus loads, to gain a better understanding of the pathogenic mechanisms of HBV. (More)
OBJECTIVES To evaluate the efficacy and safety of adefovir dipivoxil (ADV) treatment in patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB). METHODS This was a multicenter, randomized, double-blind, placebo-controlled study. It was performed in four steps. First step: subjects were randomly assigned to receive either ADV 10 mg(More)
OBJECTIVE To investigate the characteristics of mutations in pre S/S gene of HBV in asymptomatic carrier (AsC) children infected through mother-to-infant transmission and their AsC mothers with different degree of viremia. METHODS According to the levels of viremia in every pair of mother and child, 15 pairs of child and mother were divided into three(More)
OBJECTIVE To study the expression of the shortened hepatitis B surface antigen in prokaryocyte and detect the antigenic characters. METHODS Firstly, the gene fragments coding the 152 and 124 amino acids of the carboxyl terminus of hepatitis B surface antigen (HBsAg) were amplified by polymerase chain reaction (PCR). Secondly, they were cloned to plasmid(More)
OBJECTIVE To investigate the incidence of HBV reactivation and its clinical characteristics in the non-active HBsAg carriers receiving chemotherapy or immunosuppressant treatment, and to evaluate the role of nucleos(t)ide analogues against HBV reactivation. METHODS Non-active HBsAg carriers suffering from cancer, autoimmune diseases recieving(More)